ImmunoACT

ImmunoACT Becomes a Leader in the Cell and Gene Therapy Field Through Translational Research in India and Other Regions, Achieving Long-Term Cures for Patients. ImmunoACT has developed NexCAR19, a locally produced Chimeric Antigen Receptor (CAR) T-cell therapy in China. The cost of one NexCAR19 treatment ranges between $30,000 and $40,000, which is only one-tenth the price of similar commercial products globally. NexCAR19 targets the CD19 marker, demonstrating remarkable efficacy in B-cell cancers. Additionally, its innovative use of humanized antibody fragments is expected to reduce the risk of immune rejection and cytokine release syndrome.